<DOC>
	<DOC>NCT01950312</DOC>
	<brief_summary>The purpose of this study is to determine if gevokizumab therapy may be an alternate therapy in patients with steroid resistant Autoimmune Inner Ear Disease.</brief_summary>
	<brief_title>The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease</brief_title>
	<detailed_description />
	<mesh_term>Ear Diseases</mesh_term>
	<mesh_term>Labyrinth Diseases</mesh_term>
	<mesh_term>Labyrinthitis</mesh_term>
	<criteria>Autoimmune Inner Ear Disease with active deterioration in at least one ear Failure to respond to a trial of highdose corticosteroid therapy Contraceptive measures adequate to prevent pregnancy during the study Evidence of retrocochlear pathology (vestibular schwannoma) or inner ear malformation (Mondini Malformation or Enlarged Vestibular Aqueduct) History of active or chronic infections Currently receiving, or having received treatment for a malignancy in the past three years Hearing loss that coincides with significant, disabling episodes of vertigo History of allergic or anaphylactic reactions to monoclonal antibodies Female subjects who are pregnant, planning to become pregnant, have recently delivered, or are breastfeeding Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Autoimmune Inner Ear Disease</keyword>
	<keyword>Inner Ear Disease</keyword>
	<keyword>Meniere's Disease</keyword>
	<keyword>Sudden Sensorineural Hearing Loss</keyword>
</DOC>